The German pharmaceutical company Stada announced the purchase of a generic plant by the Ukrainian company Biopharma. Biopharma will concentrate on the production of blood plasma products.
According to experts, the deal amounted to 70−80 million US dollars.
In the next two to three years, the German company plans to invest about 5 million euros in the expansion of production, as well as to begin manufacturing Stada preparations in Ukraine.
According to an analytical report from Fitch Solutions, the growth rate of the Ukrainian pharmaceutical market is well ahead of the European average and this trend will continue in the coming years.
According to forecasts, sales of pharmaceutical products in Europe in 2019 will grow by 1.8% to 367.3 billion USD. The market in Ukraine will grow by 9.5% to 3.4 billion. In 2020-23, in Europe expected growth by 21.6% (up to 438.6 billion), and by 36.4% in Ukraine (up to 4.26 billion).